NEURESCUE device for Cardiac Arrest

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Long Beach Medical Center, Long Beach, CA
Cardiac Arrest+3 More
NEURESCUE device - Device
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will show whether the NEURESCUE device, which is inserted through the femoral artery, can improve blood flow to the heart and brain in adults experiencing cardiac arrest. The NEURESCUE device is used to treat cardiac arrest and has previously been approved by the FDA for a different condition. In this trial, no patients will receive a placebo.

Eligible Conditions

  • Cardiac Arrest
  • Cardiorespiratory Arrest
  • Cardiovascular Diseases

Treatment Effectiveness

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Assessed up to 10 min

Hour 1
Change in central blood pressure
Rate of occlusion success
Return of spontaneous circulation (ROSC)
Time from first vessel puncture to successful sheath insertion
Total ACLS time at initiation of the investigational procedure
Assessed up to 10 min
Successful balloon inflation within 10 minutes from first vessel puncture

Trial Safety

Trial Design

1 Treatment Group

Treatment
1 of 1
Experimental Treatment

10 Total Participants · 1 Treatment Group

Primary Treatment: NEURESCUE device · No Placebo Group · N/A

Treatment
Device
Experimental Group · 1 Intervention: NEURESCUE device · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: assessed up to 10 min
Closest Location: Long Beach Medical Center · Long Beach, CA
Photo of california 1Photo of california 2Photo of california 3
2022First Recorded Clinical Trial
1 TrialsResearching Cardiac Arrest
2 CompletedClinical Trials

Who is running the clinical trial?

neurescueLead Sponsor
2 Previous Clinical Trials
10 Total Patients Enrolled
2 Trials studying Cardiac Arrest
10 Patients Enrolled for Cardiac Arrest
David Shavelle, M.D.Principal InvestigatorLong Beach Medical Center

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.